Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Emtricitabine

FDA-approved product (capsule, oral), marketed as Emtricitabine, Emtriva.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Emtricitabine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleoside and nucleotide reverse transcriptase inhibitors
FDA pharmacologic class
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AF09

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA45.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli25.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis50.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Emtricitabine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Emtricitabine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pharmacokinetics and Pharmacodynamics of DMPA With HIV PrEP

    NCT03197961 · start 2017-11-17

    Registered record
    Registry ID
    NCT03197961
    Conditions
    HIV/AIDS; Contraception
    Interventions
    tenofovir/emtricitabine; DMPA
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2017-11-17
    Completion
    2020-12-01
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV/AIDS; Contraception
    Interventiontenofovir/emtricitabine; DMPA
    PhaseEarly phase 1
    Registry statusCompleted

  • Western Australian Pre-exposure Prophylaxis for HIV Implementation Trial

    NCT03327155 · start 2017-11-16

    Registered record
    Registry ID
    NCT03327155
    Conditions
    HIV Prevention
    Interventions
    Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-11-16
    Completion
    2020-07-20
    Enrolment
    900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Prevention
    InterventionTenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)
    PhasePhase 3
    Registry statusCompleted

  • PK and PD Study of Oral F/TAF for HIV Prevention

    NCT02904369 · start 2016-10-06

    Registered record
    Registry ID
    NCT02904369
    Conditions
    HIV
    Interventions
    Emtricitabine; Tenofovir alafenamide; Tenofovir disoproxil
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-10-06
    Completion
    2017-11-21
    Enrolment
    73

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionEmtricitabine; Tenofovir alafenamide; Tenofovir disoproxil
    PhasePhase 1
    Registry statusCompleted

  • Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women

    NCT02652624 · start 2016-02-19

    Registered record
    Registry ID
    NCT02652624
    Conditions
    HIV-1 Infection
    Interventions
    E/C/F/TAF; E/C/F/TDF; ATV; RTV; FTC/TDF; B/F/TAF
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-02-19
    Completion
    2018-11-26
    Enrolment
    472

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionE/C/F/TAF; E/C/F/TDF; ATV; RTV +2 more
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

    NCT02605954 · start 2015-11-18

    Registered record
    Registry ID
    NCT02605954
    Conditions
    HIV-1 Infection
    Interventions
    E/C/F/TAF; ABC/3TC; Third Antiretroviral Agent
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-11-18
    Completion
    2018-01-24
    Enrolment
    275

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionE/C/F/TAF; ABC/3TC; Third Antiretroviral Agent
    PhasePhase 3
    Registry statusCompleted

  • Comprehensive HIV Prevention Package for MSM in Port Elizabeth

    NCT02449733 · start 2015-05

    Registered record
    Registry ID
    NCT02449733
    Conditions
    HIV
    Interventions
    Condom choices; Condom-compatible lubricant choices; Couples HIV counseling and testing (CVCT); Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF); HIV Testing; Linkage to care; Post-exposure prophylaxis (PEP); Risk-reduction counseling
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-05
    Completion
    2017-03
    Enrolment
    101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionCondom choices; Condom-compatible lubricant choices; Couples HIV counseling and testing (CVCT); Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) +4 more
    PhaseNot applicable
    Registry statusCompleted

  • Renal Integrase Study

    NCT02351908 · start 2015-03

    Registered record
    Registry ID
    NCT02351908
    Conditions
    HIV
    Interventions
    Stribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat); Isentress® (Raltegravir 400 mg)1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet; Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-03
    Completion
    2017-04
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionStribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat); Isentress® (Raltegravir 400 mg)1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet; Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir)
    PhasePhase 4
    Registry statusCompleted

  • Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy

    NCT02302547 · start 2014-12

    Registered record
    Registry ID
    NCT02302547
    Conditions
    HIV
    Interventions
    triple therapy; dual therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-12
    Completion
    2018-09-21
    Enrolment
    224

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    Interventiontriple therapy; dual therapy
    PhasePhase 3
    Registry statusCompleted

  • PRe-Exposure Prophylaxis Acceptability & Readiness Assessments for Toronto gaY, Bisexual and Other Men Who Have Sex With Men-5

    NCT02149888 · start 2014-10

    Registered record
    Registry ID
    NCT02149888
    Conditions
    HIV; Human Immunodeficiency Virus
    Interventions
    Tenofovir/emtricitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-10
    Completion
    2016-06
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; Human Immunodeficiency Virus
    InterventionTenofovir/emtricitabine
    PhasePhase 4
    Registry statusCompleted

  • Study to Evaluate Darunavir/Ritonavir + Lamivudine Versus Continuing With Darunavir/Ritonavir + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected Subject

    NCT02159599 · start 2014-07

    Registered record
    Registry ID
    NCT02159599
    Conditions
    HIV Infection
    Interventions
    Darunavir/Ritonavir; Lamivudine; Emtricitabine/tenofovir or abacavir/lamivudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-07
    Completion
    2016-04
    Enrolment
    249

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionDarunavir/Ritonavir; Lamivudine; Emtricitabine/tenofovir or abacavir/lamivudine
    PhasePhase 4
    Registry statusCompleted

  • Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir

    NCT02104700 · start 2014-04

    Registered record
    Registry ID
    NCT02104700
    Conditions
    HIV
    Interventions
    Rilpivirine/Emtricitabine/Tenofovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2014-04
    Completion
    2016-07
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionRilpivirine/Emtricitabine/Tenofovir
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • A Pharmacokinetic Evaluation of Levonorgestrel Implant and Antiretroviral Therapy

    NCT01789879 · start 2014-03-04

    Registered record
    Registry ID
    NCT01789879
    Conditions
    HIV; Contraception
    Interventions
    Levonorgestrel; Nevirapine; Efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-03-04
    Completion
    2015-03-04
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; Contraception
    InterventionLevonorgestrel; Nevirapine; Efavirenz
    PhasePhase 2
    Registry statusCompleted

  • Factors Affecting PrEP Adherence

    NCT02411630 · start 2013-06

    Registered record
    Registry ID
    NCT02411630
    Conditions
    HIV Infection
    Interventions
    Emtricitabine/tenofovir disoproxil
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-06
    Completion
    2015-06
    Enrolment
    167

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionEmtricitabine/tenofovir disoproxil
    PhaseNot recorded
    Registry statusCompleted

  • Economic, Clinical and Quality of Life Assessment in Patients on Antiretroviral Therapy

    NCT01694017 · start 2012-11

    Registered record
    Registry ID
    NCT01694017
    Conditions
    HIV
    Interventions
    Tenofovir; Zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-11
    Completion
    2014-08
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionTenofovir; Zidovudine
    PhasePhase 4
    Registry statusCompleted

  • Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

    NCT01533259 · start 2012-01

    Registered record
    Registry ID
    NCT01533259
    Conditions
    Acquired Immunodeficiency Syndrome; HIV Infections
    Interventions
    Stribild
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-01
    Completion
    2013-07
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcquired Immunodeficiency Syndrome; HIV Infections
    InterventionStribild
    PhasePhase 3
    Registry statusCompleted